Spectrum Pharma (SPPI) Announces FDA Acceptance for Review of FUSILEV

November 29, 2010 7:19 AM EST Send to a Friend
Spectrum Pharmaceuticals (Nasdaq: SPPI) announced Monday that the U.S. Food and Drug Administration has accepted for filing and review the complete response regarding its supplemental New Drug Application for FUSILEV.

The FDA said that the the submission is a Class 2 response and the PDUFA Action date is April 29, 2011.

FUSILEV is a treatment for patients with advanced metastic colorectal cancer.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

FDA

Add Your Comment